Sensus Healthcare, Inc. (SRTS)
NASDAQ: SRTS · Real-Time Price · USD
3.190
+0.010 (0.31%)
At close: Oct 31, 2025, 4:00 PM EDT
3.229
+0.039 (1.23%)
After-hours: Oct 31, 2025, 5:15 PM EDT
Sensus Healthcare Revenue
Sensus Healthcare had revenue of $7.32M in the quarter ending June 30, 2025, a decrease of -20.82%. This brings the company's revenue in the last twelve months to $37.56M, up 3.29% year-over-year. In the year 2024, Sensus Healthcare had annual revenue of $41.81M with 71.31% growth.
Revenue (ttm)
$37.56M
Revenue Growth
+3.29%
P/S Ratio
1.39
Revenue / Employee
$695,630
Employees
54
Market Cap
52.44M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 41.81M | 17.40M | 71.31% |
| Dec 31, 2023 | 24.41M | -20.13M | -45.20% |
| Dec 31, 2022 | 44.53M | 17.49M | 64.68% |
| Dec 31, 2021 | 27.04M | 17.47M | 182.36% |
| Dec 31, 2020 | 9.58M | -17.69M | -64.87% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.11B |
SRTS News
- 1 day ago - Sensus Healthcare Announces the Passing of Director Bill McCall - Business Wire
- 9 days ago - Sensus Healthcare to Report Third Quarter 2025 Financial Results and Hold Business Update Conference Call on November 6 - Business Wire
- 23 days ago - SENSUS INVESTIGATION REMINDER: Bragar Eagel & Squire, Reminds Sensus Healthcare Investors to Contact the Firm Regarding Ongoing Investigation on Behalf of Sensus Stockholders - GlobeNewsWire
- 5 weeks ago - Study Published in Dermatologic Therapy Shows Efficacy of Sensus Healthcare's SRT Combined with Punch Excision to Treat Keloids - Business Wire
- 2 months ago - Sensus Healthcare, Inc. Investors: Company Investigated by the Portnoy Law Firm - GlobeNewsWire
- 2 months ago - SRTS Investors Have Opportunity to Join Sensus Healthcare, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
- 3 months ago - Sensus Healthcare, Inc. (SRTS) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Sensus Healthcare Reports Second Quarter 2025 Financial Results - Business Wire